The Major players within the OTC market are:
- Johnson & Johnson
- Pfizer
- GlaxoSmithKline
- Wyeth
- Bayer
Source:
The OTC Outlook to 2007
Reuters Business Insight: Healthcare
http://www.bioportfolio.com/cgi-bin/acatalog/rbhc0090t.pdf
=================
Johnson & Johnson
=================
Research & Development:
?Research activities represent a significant part of the Company's
business. These expenditures relate to the development of new
products, improvement of existing products, technical support of
products and compliance with governmental regulations for the
protection of the consumer.?
Worldwide costs of research activities, excluding the in-process
research & development charges, were as follows:
(Millions of Dollars) 2003 2002 2001
--------------------- ------- ------- -------
Research expense $ 4,684 3,957 3,591
Percent of sales 11.2% 10.9% 11.1%
?Research & development expense as a percent of sales for the
Pharmaceutical segment was 16.4% for 2003, 15.7% for 2002
and 16.6% for
2001 while averaging 6.7%, 6.6% and 6.5% in the Consumer and Medical
Devices and Diagnostics segments combined for 2003, 2002 and 2001,
respectively.?
SECURITIES AND EXCHANGE COMMISSION
http://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv13.txt
SECURITIES AND EXCHANGE COMMISSION
JOHNSON & JOHNSON
FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 28, 2003
?The costs of Johnson & Johnson's worldwide research activities
relating to the development of new products, the improvement of
existing products, technical support of products and compliance with
governmental regulations for the protection of the consumer amounted
to $4,684, $3,957, and $3,591 million for fiscal years 2003, 2002 and
2001, respectively. These costs are charged directly to income in the
year in which incurred. All research was sponsored by Johnson &
Johnson.?
SECURITIES AND EXCHANGE COMMISSION
http://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471e10vk.txt
?Consumer segment sales in 2003 were $7.4 billion, or an increase of
13.2%, over 2002 with operational growth accounting for 9.4% of the
total growth and 3.8% due to currency fluctuations. U.S. Consumer
segment sales were $4.0 billion, an increase of 10.1%, while
international sales were $3.4 billion, or an increase of 17.0%, with
8.6% due to operations and 8.4% due to currency fluctuations over
2002. Consumer segment sales growth is attributable to strong sales
performance in the major franchises in this segment including Skin
Care, Baby & Kids Care and the McNeil Consumer over-the-counter
pharmaceutical and nutritional products. The Skin Care franchise sales
in 2003 were $1.8 billion, representing a 14.4% increase over 2002.
This growth was attributed to solid sales in NEUTROGENA brand
products, especially in international markets, and AVEENO brand
products in the facial care line as well as new products launched in
the latter half of 2003. The Baby & Kids Care franchise grew by 12.8%
to $1.3 billion in 2003. Growth in this franchise was led by new
products launched in 2003 including JOHNSON'S SOFTWASH and JOHNSON'S
SOFTLOTION. McNeil Consumer over-the-counter pharmaceutical and
nutritional products sales were $2.0 billion, an increase of 13.6%
over 2002. Contributing to this growth was the continued growth of
SPLENDA brand no calorie sweetener and the increased sales in the
MOTRIN and TYLENOL brand products due to an early and strong cold and
flu season. Another franchise contributing to the overall sales growth
in the Consumer segment was the Women's Health franchise that achieved
sales of $1.4 billion, a 9.6% increase over 2002. Strong growth in the
sanitary protection products in international markets contributed to
the growth in this franchise.?
SECURITIES AND EXCHANGE COMMISSION
http://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv13.txt
Key Numbers
Fiscal Year-End December
2003 Sales (mil.) $41,862.0
1-Year Sales Growth 15.3%
2003 Net Income (mil.) $7,197.0
1-Year Net Income Growth 9.1%
2003 Employees 110,600
1-Year Employee Growth 2.1%
Key Numbers and Fact Sheet at Hoover?s
http://www.hoovers.com/johnson-&-johnson/--ID__10824--/free-co-factsheet.xhtml
==========
Pfizer Inc
==========
Research and Development Expenses (R&D)
?R&D expenses increased 38% in 2003 and 8% in 2002. In 2003,
year-over-year growth for R&D spending is attributable to the
incremental expenditures associated with the consolidation of
Pharmacia-related activity subsequent to the acquisition date and
increased support of the advanced-stage development portfolio,
partially offset by initial cost synergies from Pharmacia-related
restructuring activities. In 2002, growth is attributable to increased
support of the advanced-stage R&D portfolio, higher costs as a result
of the recent expansion of facilities and increased information
technology costs due to the continued implementation of
enterprise-wide resource management systems.?
YEAR ENDED DECEMBER 31
(MILLIONS) 2003 2002 2001 2000
Revenues $ 45,188 $ 32,373 $ 29,024 $ 26,045
Research
and development 7,131 5,176 4,776 4,374
***** In 2003, Research and Development expenses were approximately
15.8% of sales.
PORTIONS OF THE 2003 FINANCIAL REPORT
http://www.sec.gov/Archives/edgar/data/78003/000095012304003064/y94722exv13.htm
Key Numbers
Fiscal Year-End December
2003 Sales (mil.) $45,188.0
1-Year Sales Growth 39.6%
2003 Net Income (mil.) $3,910.0
1-Year Net Income Growth (57.2%)
2003 Employees 122,000
1-Year Employee Growth 24.5%
http://www.hoovers.com/pfizer-inc/--ID__11175--/free-co-factsheet.xhtml
SECURITIES AND EXCHANGE COMMISSION
FORM 10 - K
PFIZER INC. Consumer Healthcare Segment
?Our Consumer Healthcare business is one of the largest in the world.
We market many of the world?s best-known OTC medications for oral
care, upper respiratory health, tobacco dependence, gastrointestinal
health, skin care, eye care and hair growth.
In 2003, Consumer Healthcare revenues increased 20%, to $3 billion,
primarily due to the inclusion of legacy Pharmacia products as well as
the strong performance of Listerine mouthwash and the favorable impact
of foreign exchange. Revenues from this segment contributed 7% of our
total revenues in 2003 and 8% in each of 2002 and 2001.
Research and Product Development
Innovation by our research and development operations is very
important to the Company?s success. Our goal is to discover, develop
and bring to market innovative products that address major unmet
medical needs. This goal has been supported by our substantial
research and development investments. We spent $7.1 billion in 2003,
$5.2 billion in 2002 and $4.8 billion in 2001 on research and
development.?
http://www.hoovers.com/free/co/secdoc.xhtml?ipage=2660025&doc=1
Pfizer
Pharma Revenues $28,288
Total Revenues $32,373
Net Income $9,126
R&D Budget $5,176
http://www.contractpharma.com/JulyAug031.htm#Pfizer
?Revenues from operations outside the U.S. of $18.3 billion accounted
for 40.6% of our total revenues in 2003. Revenues exceeded $500
million in each of ten countries outside the U.S. in 2003. The U.S.
was the only country to contribute more than 10% of our total
revenues. Japan is our second-largest national market, with 5.9% of
our revenues in 2003, 6.1% of our revenues in 2002 and 6.2% of our
revenues in 2001.?
Consumer Healthcare Segment
?Our Consumer Healthcare business is one of the largest in the world.
We market many of the world?s best-known OTC medications for oral
care, upper respiratory health, tobacco dependence, gastrointestinal
health, skin care, eye care and hair growth.?
?In 2003, Consumer Healthcare revenues increased 20%, to $3 billion,
primarily due to the inclusion of legacy Pharmacia products as well as
the strong performance of Listerine mouthwash and the favorable impact
of foreign exchange. Revenues from this segment contributed 7% of our
total revenues in 2003 and 8% in each of 2002 and 2001.?
SECURITIES AND EXCHANGE COMMISSION
http://www.sec.gov/Archives/edgar/data/78003/000095012304003064/y94722e10vk.htm#008
===================
GlaxoSmithKline plc
===================
Key Numbers
Fiscal Year-End December
2003 Sales (mil.) $38,238.0
1-Year Sales Growth 11.9%
2003 Net Income (mil.) $7,997.0
1-Year Net Income Growth 26.1%
2002 Employees 106,166
1-Year Employee Growth (1.6%)
http://www.hoovers.com/glaxosmithkline-plc/--ID__41781--/free-co-factsheet.xhtml
From the 2003 GlaxoSmithKline annual report:
In 2003 GlaxoSmithKline invested nearly £2.7 billion in pharmaceuticals R&D.
2003 Sales R&D
(M. Euros) (M. Euros)
Pharmaceuticals 18,181 2,704
Consumer Healthcare 3,260 87
Total 21,441 2,791
http://www.gsk.com/financial/reps03/annual_report2003.pdf
***** In 2003, Research and Development expenses for Pharmaceuticals
were approximately 14.9% of sales.
***** In 2003, Research and Development expenses for Consumer
Healthcare were approximately 2.7% of sales.
***** In 2003, Research and Development expenses for Pharmaceuticals
and Consumer Healthcare together were approximately 13% of sales.
GSK Financial Reports
http://www.gsk.com/financial/reps03/index.htm
GSK Annual review
http://www.gsk.com/financial/reps03/annual_review2003.pdf
GlaxoSmithKline
Pharma Revenues $27,060
Total Revenues $31,898
Net Income $6,958
R&D Budget $4,108
http://www.contractpharma.com/JulyAug031.htm#GlaxoSmithKline
=====
Wyeth (Formerly American Home Products Corporation).
=====
Year Ended December 31,
2003 2002 2001
Net Revenue $15,850,632 $14,584,035 $13,983,745
R&D Expenses 2,093,533 2,080,191 1,869,679
**** In 2003, Research and Development expenses were approximately
13.2% of sales.
?Research and development expenses increased 1% for 2003. The increase
was partially due to higher clinical grant spending, primarily in the
field of women's health care and infectious diseases, and higher
cost-sharing expenditures relating to pharmaceutical collaborations
offset, in part, by lower other research operating expenses (including
lower chemical and material costs). Pharmaceuticals research and
development expenditures accounted for 93% of total research and
development expenditures in both 2003 and 2002. Pharmaceuticals
research and development expenses, as a percentage of worldwide
Pharmaceuticals net revenue, exclusive of nutritional sales and
alliance revenue, were 17% and 19% in 2003 and 2002, respectively. The
increase in research and development expenses also was due to higher
expenditures relating to Animal Health line extensions and combination
product projects.?
?Research and development expenses increased 11% for 2002 due
primarily to increased headcount, clinical grant spending,
cost-sharing expenditures relating to pharmaceutical collaborations
and other research operating expenses (including higher chemical and
material costs) offset, in part, by lower payments under licensing
agreements. Pharmaceuticals research and development expenditures
accounted for 93% and 94% of total research and development
expenditures in 2002 and 2001, respectively. Pharmaceuticals research
and development expenses, as a percentage of worldwide Pharmaceuticals
net revenue, exclusive of nutritional sales and alliance revenue, were
19% and 18% in 2002 and 2001, respectively.?
SECURITIES AND EXCHANGE COMMISSION
http://www.sec.gov/Archives/edgar/data/5187/000000518704000048/y94966.txt
SECURITIES AND EXCHANGE COMMISSION
http://www.sec.gov/Archives/edgar/data/5187/000000518704000048/0000005187-04-000048-index.htm
=====
Bayer
=====
Net Sales (Million Euros)
2002 29,634
2003 28,567
Change in % -3.6%
Research and development expenses (Million Euros)
2002 2577
2003 2414
Change in % -6.3%
Bayer: 2003 Annual Report
http://www.bayer.com/annualreport_2003/pdf/en_ar_complete.pdf
In 2003, Research and Development expenses were approximately
8.5% of sales.
In 2002, Research and Development expenses were approximately
8.7% of sales.
----------------------
Financial Statements
Page 8
Key data by segment
Consumer Care - Diagnostics
2003
Net Sales: 3,336 (Million Euros)
Research and Development: 211(Million Euros)
Pharmaceuticals, Biological Products
2003
Net Sales: 4,745 (Million Euros)
Research and Development: 966(Million Euros)
http://www.bayer.com/annualreport_2003/pdf/en_financialstatements.pdf
Key Numbers
http://www.hoovers.com/bayer-group/--ID__41808--/free-co-factsheet.xhtml
Fact Sheet
http://www.hoovers.com/bayer/--ID__41808--/free-co-fin-factsheet.xhtml
Bayer Annual Report
http://www.bayer.com/annualreport_2003/
Search criteria
Top OR leading OR major OTC pharmaceutical companies
SEC Filings
Companies Annual Reports
SEC
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&SIC=2834
Thank you for your question and I hope this response has provided you
with the information you were seeking.
Best regards,
Bobbie7-ga |
